Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$57,735 Mln
Revenue (TTM)
$21,923 Mln
Net Profit (TTM)
$1,757 Mln
ROE
0.1 %
ROCE
3.6 %
P/E Ratio
26
P/B Ratio
1.8
Industry P/E
56.97
EV/EBITDA
12.7
Div. Yield
2.6 %
Debt to Equity
0.7
Book Value
$--
EPS
$6.1
Face value
--
Shares outstanding
284,466,650
CFO
$28,585.00 Mln
EBITDA
$32,854.00 Mln
Net Profit
$11,716.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Becton Dickinson and Company (BDX)
| -19.0 | -11.4 | -19.6 | -31.0 | -12.6 | -7.6 | 0.9 |
|
BSE Sensex
| -9.4 | -8.1 | -9.3 | 3.4 | 9.8 | 9.0 | 12.0 |
|
S&P 100
| -6.0 | -3.0 | -3.5 | 18.4 | 22.0 | 12.5 | 13.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Becton Dickinson and Company (BDX)
| -14.5 | -6.9 | -4.1 | 3.7 | 1.9 | -6.8 | 22.2 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Becton Dickinson and Company (BDX)
|
157.1 | 57,735.4 | 21,923.0 | 1,757.0 | 12.0 | 6.9 | 26 | 1.8 |
| 107.8 | 1,87,721.9 | 44,328.0 | 6,524.0 | 20.0 | 13.1 | 29 | 3.6 | |
| 71.5 | 1,02,581.0 | 20,074.0 | 2,886.0 | 14.7 | 12.5 | 35.6 | 4.2 | |
| 192.1 | 1,32,461.4 | 24,568.0 | 3,614.0 | 18.3 | 7.1 | 37.2 | 2.9 | |
| 83.4 | 47,515.3 | 6,067.6 | 1,073.5 | 20.4 | 10.6 | 45.2 | 4.8 | |
| 583.0 | 45,820.3 | 4,303.7 | 1,059.5 | 31.7 | 66.2 | 43.9 | 28.5 | |
| 481.2 | 1,67,678.3 | 10,064.7 | 2,856.0 | 29.3 | 16.7 | 59.8 | 9.5 | |
| 229.0 | 33,694.9 | 5,398.1 | 1,485.9 | 34.0 | 24.2 | 22.8 | 5.3 | |
| 346.7 | 1,28,878.1 | 25,116.0 | 3,246.0 | 17.9 | 15.1 | 40.1 | 5.8 | |
| 465.1 | 1,72,506.1 | 44,556.0 | 6,737.0 | 19.5 | 13.1 | 26.2 | 3.3 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical... industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care Read more
President, CEO & Chairman
Mr. Thomas E. Polen Jr.
President, CEO & Chairman
Mr. Thomas E. Polen Jr.
Headquarters
Franklin Lakes, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Becton Dickinson and Company (BDX) is $157.11 (NYSE) as of 18-Mar-2026 14:40 EDT. Becton Dickinson and Company (BDX) has given a return of -12.63% in the last 3 years.
The P/E ratio of Becton Dickinson and Company (BDX) is 26.04 times as on 13-Mar-2026, a 54 discount to its peers’ median range of 56.97 times.
The P/B ratio of Becton Dickinson and Company (BDX) is 1.80 times as on 13-Mar-2026, a 40 discount to its peers’ median range of 3.02 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
32.03
|
2.12
|
|
2024
|
41.09
|
2.71
|
|
2023
|
50.99
|
2.93
|
|
2022
|
35.90
|
2.53
|
|
2021
|
33.91
|
3.00
|
The 52-week high and low of Becton Dickinson and Company (BDX) are Rs 233.51 and Rs 156.35 as of 19-Mar-2026.
Becton Dickinson and Company (BDX) has a market capitalisation of $ 57,735 Mln as on 13-Mar-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Becton Dickinson and Company (BDX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-4.53
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.